Nabriva Therapeutics plc – (NBRV) Downgraded by Zacks Investment Research to Hold

Zacks Investment Research cut shares of Nabriva Therapeutics plc – (NASDAQ:NBRV) from a buy rating to a hold rating in a research report sent to investors on Saturday.

According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “

NBRV has been the subject of a number of other research reports. SunTrust Banks, Inc. assumed coverage on Nabriva Therapeutics plc – in a research report on Friday, August 25th. They set a buy rating and a $20.00 target price for the company. Cantor Fitzgerald restated a buy rating and set a $16.00 target price on shares of Nabriva Therapeutics plc – in a research report on Friday, September 1st. HC Wainwright boosted their target price on Nabriva Therapeutics plc – from $18.00 to $20.00 and gave the stock a buy rating in a research report on Wednesday. Needham & Company LLC restated a buy rating and set a $18.00 target price (up previously from $15.00) on shares of Nabriva Therapeutics plc – in a research report on Tuesday, September 19th. Finally, ValuEngine downgraded Nabriva Therapeutics plc – from a hold rating to a sell rating in a research report on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. Nabriva Therapeutics plc – has an average rating of Buy and an average price target of $19.03.

Nabriva Therapeutics plc – (NASDAQ NBRV) traded up $0.39 during mid-day trading on Friday, hitting $6.14. The stock had a trading volume of 361,540 shares, compared to its average volume of 391,060. Nabriva Therapeutics plc – has a 12 month low of $3.52 and a 12 month high of $14.10.

Nabriva Therapeutics plc – (NASDAQ:NBRV) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($5.83) by $5.29. The firm had revenue of $1.05 million for the quarter, compared to the consensus estimate of $1.34 million. research analysts forecast that Nabriva Therapeutics plc – will post -2.35 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Nabriva Therapeutics plc – (NBRV) Downgraded by Zacks Investment Research to Hold” was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.com-unik.info/2017/11/05/nabriva-therapeutics-plc-nbrv-downgraded-by-zacks-investment-research-to-hold.html.

In related news, major shareholder Hbm Healthcare Investments (Ca sold 17,790 shares of the company’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $10.50, for a total value of $186,795.00. Following the completion of the sale, the insider now owns 2,373,387 shares in the company, valued at $24,920,563.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Vivo Capital Viii, Llc acquired 52,631 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The stock was bought at an average price of $9.46 per share, with a total value of $497,889.26. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 57,219 shares of company stock valued at $535,919 and sold 74,840 shares valued at $714,161. Corporate insiders own 2.75% of the company’s stock.

Several institutional investors have recently made changes to their positions in NBRV. Almanack Investment Partners LLC. increased its holdings in shares of Nabriva Therapeutics plc – by 482.2% in the second quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock worth $1,633,000 after acquiring an additional 751,366 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of Nabriva Therapeutics plc – by 19.6% in the second quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock worth $553,000 after acquiring an additional 8,650 shares in the last quarter. Finally, Nationwide Fund Advisors increased its holdings in shares of Nabriva Therapeutics plc – by 4.6% in the second quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock worth $2,032,000 after acquiring an additional 7,924 shares in the last quarter. Institutional investors own 50.24% of the company’s stock.

Nabriva Therapeutics plc – Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Analyst Recommendations for Nabriva Therapeutics plc - (NASDAQ:NBRV)

What are top analysts saying about Nabriva Therapeutics plc -? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nabriva Therapeutics plc - and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit